- Home
- VANI vs RLMD Comparison
VANI vs RLMD Comparison
Compare VANI & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- RLMD
- Stock Information
- Founded
- VANI 1998
- RLMD 2004
- Country
- VANI United States
- RLMD United States
- Employees
- VANI N/A
- RLMD N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- VANI Health Care
- RLMD Health Care
- Exchange
- VANI Nasdaq
- RLMD Nasdaq
- Market Cap
- VANI 81.2M
- RLMD 67.7M
- IPO Year
- VANI 2014
- RLMD N/A
- Fundamental
- Price
- VANI $1.47
- RLMD $2.00
- Analyst Decision
- VANI Strong Buy
- RLMD Hold
- Analyst Count
- VANI 1
- RLMD 2
- Target Price
- VANI $4.00
- RLMD $1.00
- AVG Volume (30 Days)
- VANI 154.3K
- RLMD 387.8K
- Earning Date
- VANI 11-12-2025
- RLMD 11-06-2025
- Dividend Yield
- VANI N/A
- RLMD N/A
- EPS Growth
- VANI N/A
- RLMD N/A
- EPS
- VANI N/A
- RLMD N/A
- Revenue
- VANI N/A
- RLMD N/A
- Revenue This Year
- VANI N/A
- RLMD N/A
- Revenue Next Year
- VANI N/A
- RLMD N/A
- P/E Ratio
- VANI N/A
- RLMD N/A
- Revenue Growth
- VANI N/A
- RLMD N/A
- 52 Week Low
- VANI $0.91
- RLMD $0.24
- 52 Week High
- VANI $1.80
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- VANI 56.91
- RLMD 56.08
- Support Level
- VANI $1.36
- RLMD $1.87
- Resistance Level
- VANI $1.45
- RLMD $2.14
- Average True Range (ATR)
- VANI 0.07
- RLMD 0.30
- MACD
- VANI -0.01
- RLMD -0.05
- Stochastic Oscillator
- VANI 68.00
- RLMD 20.75
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.